NEWS RELEASE
August 7, 2023
FDA Grants Orphan Drug Designation to NS-089/NCNP-02 for the
Treatment of Duchenne Muscular Dystrophy
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
PARAMUS, NJ: August 7, 2023 – NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
The FDA issues Orphan Drug Designations to support the development and evaluation of new treatments to prevent, diagnose, or treat a rare disease or condition.
NS-089/NCNP-02 previously received Rare Pediatric Disease Designation from the FDA in June 2023 and Breakthrough Therapy Designation in July 2023.
NS-089/NCNP-02 is an antisense nucleotide discovered through joint research between NS Pharma’s parent company, Nippon Shinyaku, and the National Center of Neurology and Psychiatry (Kodaira City; President, Kazuyuki Nakagome).
Clinical development of NS-089/NCNP-02 includes a planned Phase 2 study in the United States conducted by NS Pharma and a Phase 2 study conducted in Japan by Nippon Shinyaku. Additional details will be provided once the trials are ready to begin enrolling participants.
About Duchenne Muscular Dystrophy (Duchenne)
Duchenne is a progressive form of muscular dystrophy that occurs primarily in males. Duchenne causes progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of Duchenne may include delayed ability to sit, stand or walk.
There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact:
NEWS RELEASE
July 28, 2023
FDA Grants Breakthrough Therapy Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
PARAMUS, NJ: July 28, 2023 – NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS- 089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
The Breakthrough Therapy Designation for NS-089/NCNP-02 is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan.1 The FDA issues Breakthrough Therapy Designation to expedite the development and review of medicines which are intended to treat serious or life-threatening diseases. The criteria require preliminary clinical evidence that indicates the drug may demonstrate substantial improvement over available therapies on a clinically meaningful endpoint(s). In June 2023, NS-089/NCNP-02 was granted Rare Pediatric Disease Designation by the FDA.
NS-089/NCNP-02 is an antisense nucleotide discovered through joint research between NS Pharma’s parent company, Nippon Shinyaku, and the National Center of Neurology and Psychiatry (Kodaira City, President: Kazuyuki Nakagome).
Clinical development of NS-089/NCNP-02 includes a planned Phase 2 study in the United States conducted by NS Pharma and a Phase 2 study conducted in Japan by
Nippon Shinyaku. Additional details will be provided once the trials are ready to begin enrolling participants.
About Duchenne Muscular Dystrophy (Duchenne)
Duchenne is a progressive form of muscular dystrophy that occurs primarily in males. Duchenne causes progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of Duchenne may include delayed ability to sit, stand or walk.
There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact: media@nspharma.com
Reference
1. National Center of Neurology and Psychiatry Press release on March 17, 2022.
https://www.ncnp.go.jp/topics/2022/20220317e.html
NEWS RELEASE
July 7, 2023
FDA Grants Rare Pediatric Disease Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
PARAMUS, NJ: July 7, 2023 – NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Rare Pediatric Disease Designation to NS- 089/NCNP-02 (brogidirsen) an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
The FDA’s Rare Pediatric Disease Designation is granted for treatments intended for serious or life-threatening diseases that affect children under the age of 18 and less than 200,000 patients in the U.S.
NS-089/NCNP-02 is an antisense nucleotide discovered through joint research between NS Pharma’s parent company, Nippon Shinyaku, and the National Center for Psychiatry and Neurological Medicine (Kodaira City, President: Kazuyuki Nakagome).
Clinical development of NS-089/NCNP-02 includes a planned Phase 2 study in the United States conducted by NS Pharma and a Phase 2 study conducted in Japan by Nippon Shinyaku. Additional details will be provided once the trials are ready to begin enrolling participants.
About Duchenne Muscular Dystrophy (Duchenne)
Duchenne is a progressive form of muscular dystrophy that occurs primarily in males.
Duchenne causes progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of Duchenne may include delayed ability to sit, stand or walk.
There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact:
NEWS RELEASE
June 15, 2023
NS Pharma Announces FDA Clearance to Initiate a Phase I/II Study for NS-050/NCNP-03, an Exon 50 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy
NS-050/NCNP-03 is NS Pharma’s second exon skipping investigational therapy to receive FDA clinical study initiation clearance in 2023. Their exon 44 skipping treatment, NS-089/NCNP-02 was cleared on March 31, 2023.
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
PARAMUS, NJ: June 15, 2023 – NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has agreed to the planned Phase I/II study of
NS-050/NCNP-03, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 50 skipping therapy. Study assessments will include dystrophin production, muscle strength, mobility and functional exercise capacity.
“This is the second trial clearance from the FDA that NS Pharma has received this year and marks the third candidate from our R&D pipeline to begin clinical trials in Duchenne,” said Tsugio Tanaka, President, NS Pharma, Inc. “Our rapid development plans reflect the urgent needs of the Duchenne community and our commitment to extending the impact of our exon skipping technology.”
NS Pharma’s parent company, Nippon Shinyaku, plans to begin clinical trial enrollment for NS-050/NCNP-03 in the US during the second half of 2023. Additional details will be provided once the trial is ready to begin enrolling participants.
“Exon skipping therapies have the potential to treat a wide range of patients with Duchenne, but more than half of Duchenne patients potentially amenable to exon skipping therapy have no approved treatment options that target their specific mutation,” said Vamshi Rao, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago. “That is why it is exciting that this year we are beginning studies of two treatments that have the potential to reach even more Duchenne patients with targeted exon skipping therapies.”
In addition to NS-050/NCNP-03, NS Pharma’s parent company, Nippon Shinyaku, has three investigational exon skipping candidates in various stages of preclinical development.
About Duchenne Muscular Dystrophy (Duchenne)
Duchenne is a progressive form of muscular dystrophy that occurs primarily in males. Duchenne causes progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of Duchenne may include delayed ability to sit, stand or walk.
There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact:
May 9, 2023
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published in the Journal of Neuromuscular Diseases
Data were from a completed four-year study (up to Week 216) of the open-label extension trial of a VILTEPSO Phase 2 study
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
Paramus, NJ: May 9, 2023 – NS Pharma is pleased to announce that previously reported long-term efficacy and safety data (final visit up to Week 216) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) have been published in the May issue of the Journal of Neuromuscular Diseases. The article, “Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study,” is freely available under open access (click here).
“In this extension study it was encouraging to see that, compared to the CINRG DNHS control group, Viltepso-treated patients showed maintenance of motor function through the first two years of treatment and experienced delay of disease progression over the following two years of treatment, whereas the control group declined over this same four-year time period,” said Leslie Magnus, MD, Vice President, Medical Affairs. “NS Pharma is pleased that these data support the role of VILTEPSO as an important treatment strategy for DMD patients who are amenable to exon 53 skipping.”
The data published in the Journal of Neuromuscular Diseases are from an open-label trial (N=16) that is the extension of a previous 24-week Phase 2 trial in North America. All 16 patients aged 4 to
<10 years with DMD amenable to exon 53 skipping at baseline in the 24-week study elected to enroll in this long-term trial to continue evaluation of motor function and safety. Assessments of timed function tests (Time to Stand, Time to Run/Walk, Time to Climb 4 Stairs) were compared to a group- matched DMD historical control drawn from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG DNHS). Both groups received a stable dose of glucocorticoid treatment.
Efficacy results at Week 205 for VILTEPSO compared to the CINRG DNHS control group for the primary endpoint of mean change from baseline for Time to Stand was 2.7 seconds vs. 8.3 seconds, respectively.
The most frequently reported adverse events were mild to moderate and included cough, nasopharyngitis, rash, pyrexia, and vomiting. This safety profile was similar to that seen in the previous short-term study. There were no treatment-related serious adverse events and no treatment discontinuations.
About VILTEPSO® (viltolarsen) injection
Prior to its approval in the U.S. in August 2020, VILTEPSO was granted Priority Review as well as Rare Pediatric Disease, Orphan Drug and Fast Track Designations. In March 2020, VILTEPSO was approved in Japan for the treatment of patients with DMD who are amenable to exon 53 skipping therapy. Prior to its approval in Japan, VILTEPSO was granted with the SAKIGAKE designation, Orphan Drug designation, and designation of Conditional Early Approval System.
Indication
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Safety Information
Warnings and Precautions: Kidney toxicity was observed in animals who received viltolarsen. Although kidney toxicity was not observed in the clinical studies with VILTEPSO, the clinical experience with VILTEPSO is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VILTEPSO. Serum creatinine may not be a reliable measure of kidney function in DMD patients.
Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. Consider also measuring glomerular filtration rate before starting VILTEPSO. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to- creatinine ratio every three months.
Urine should be free of excreted VILTEPSO for monitoring of urine protein. Obtain urine either prior to VILTEPSO infusion, or at least 48 hours after the most recent infusion. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, which has the potential to generate a false positive result due to cross reaction with any VILTEPSO in the urine. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
Adverse Reactions: The most common adverse reactions include upper respiratory tract infection, injection site reaction, cough, and pyrexia.
To report an adverse event, or for general inquiries, please call NS Pharma Medical Information at 1- 866-NSPHARM (1-866-677-4276)
For more information about VILTEPSO, see full Prescribing Information.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information,
please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact:
NEWS RELEASE
April 14, 2023
NS Pharma Announces FDA Clearance to
Initiate Phase II Study for NS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
PARAMUS, NJ: April 14, 2023, – NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has agreed to the planned Phase II study of NS-089/NCNP- 02 for Duchenne muscular dystrophy. NS-089/NCNP-02 is an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
“Progress has been made in the treatment of Duchenne, but patients and families need new and more treatment options,” said Vamshi Rao, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago. “There are currently no available antisense treatments that target Duchenne patients amenable to exon 44 skipping therapy, which is why I am excited about this program and the potential advance of effective treatments for Duchenne muscular dystrophy.”
Study efficacy measures will include the expression of dystrophin protein and motor function. Trial details will be made available through ClinicalTrials.gov. Additional information will be provided once the trial is ready to begin enrolling.
“We are pleased to announce FDA’s clearance to proceed with our Phase II clinical trial in our endeavor to help patients with Duchenne amenable to exon 44 skipping therapy,” said Takeshi Seita, Vice President, R&D at NS Pharma, Inc. “We are confident in our exon skipping drug discovery platform and excited about the future potential of our development program.”
In addition to NS-089/NCNP-02, NS Pharma’s parent company, Nippon Shinyaku, has four investigational exon skipping candidates in various stages of preclinical development.
About Duchenne Muscular Dystrophy (Duchenne)
Duchenne is a progressive form of muscular dystrophy that occurs primarily in males.
Duchenne causes progressive weakness and loss of skeletal, cardiac, and pulmonary muscles. Early signs of Duchenne may include delayed ability to sit, stand or walk. There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact:
Results of a 4-Year Viltolarsen Extension Study of Functional and Safety Outcomes
March 19, 2023
VILTEPSO® (viltolarsen) injection Open Label Extension Clinical Trial Data Scheduled for
Presentation at the MDA Clinical & Scientific Conference 2023
Data were from a final four-year analysis (up to Week 216) of the open-label extension trial of a VILTEPSO Phase 2 study
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Dr. Toru Nakai)
Paramus, NJ: March 19, 2023 – NS Pharma is pleased to announce participation in the Muscular Dystrophy Association’s (MDA) Clinical & Scientific Congress 2023 being held in Dallas, Texas.
The company will be presenting previously reported long-term efficacy and safety data (final analysis up to Week 216) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen).
The presentation will be given by Edward Smith, MD, Duke University School of Medicine. For more information, please visit the MDA Congress website to view the abstract: https://www.mdaconference.org/abstract-library/results-of-a-4-year-viltolarsen-extension-study-of- functional-and-safety-outcomes/
“There have been amazing scientific advances in the treatment of Duchenne, which is why it is important to keep the community informed about existing therapeutic options and the long-term evidence these treatments have generated,” said Dr. Smith. “The Muscular Dystrophy Association is one of the premier advocacy groups supporting the Duchenne community and I am pleased to take part in this year’s knowledge sharing at the organization’s Clinical & Scientific Congress on behalf of NS Pharma.”
About VILTEPSO® (viltolarsen) injection
Prior to its approval in the U.S. in August 2020, VILTEPSO was granted Priority Review as well as Rare Pediatric Disease, Orphan Drug and Fast Track Designations. In March 2020, VILTEPSO was approved in Japan for the treatment of patients with DMD who are amenable to exon 53 skipping therapy. Prior to its approval in Japan, VILTEPSO was granted with the SAKIGAKE designation, Orphan Drug designation, and designation of Conditional Early Approval System.
Indication
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Safety Information
Warnings and Precautions: Kidney toxicity was observed in animals who received viltolarsen. Although kidney toxicity was not observed in the clinical studies with VILTEPSO, the clinical experience with VILTEPSO is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VILTEPSO. Serum creatinine may not be a reliable measure of kidney function in DMD patients.
Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. Consider also measuring glomerular filtration rate before starting VILTEPSO. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to- creatinine ratio every three months.
Urine should be free of excreted VILTEPSO for monitoring of urine protein. Obtain urine either prior to VILTEPSO infusion, or at least 48 hours after the most recent infusion. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, which has the potential to generate a false positive result due to cross reaction with any VILTEPSO in the urine. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
Adverse Reactions: The most common adverse reactions include upper respiratory tract infection, injection site reaction, cough, and pyrexia.
To report an adverse event, or for general inquiries, please call NS Pharma Medical Information at 1- 866-NSPHARM (1-866-677-4276)
For more information about VILTEPSO, see full Prescribing Information.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact:
February 17, 2023
NS Pharma Announces First Patient Enrolled in
Phase 2 Study to Assess Efficacy and Safety of NS-018 Compared to Best Available Therapy (BAT) in Patients With Myelofibrosis
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
Paramus, NJ: February 17, 2023 – NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer.
The Phase 2b study is an open-label, multicenter, randomized, controlled, 2-arm study to assess the efficacy and safety of orally administered NS-018 versus best available therapy in subjects with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (Platelet Count <50,000/μL).
ClinicalTrials.gov identifier: NCT04854096
(https://clinicaltrials.gov/ct2/show/NCT04854096)
About Myelofibrosis (MF)
MF is caused by buildup of excessive scar tissue in the bone marrow, which impairs the body’s ability to produce blood cells.1 In addition to impaired blood cell production, MF often leads to enlargement of the spleen (splenomegaly) which can lead to feelings of abdominal pain and pressure.1 Other common symptoms include fatigue, bone pain, fever, and weight loss.1 MF can be diagnosed at any age but is most common in men and women 65 years or older.1 The median survival of patients with MF is approximately six years.1 Several gene mutations are associated with MF, and the most common mutation is to the Janus kinase 2 (JAK2) gene.2
About NS-018
NS-018 is a highly selective and potent inhibitor of JAK2 developed by scientists from Nippon
Shinyaku and was recently granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).
NEWS RELEASE
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
U.S. Media Contact:
References:
Accessed at: https://www.mpnresearchfoundation.org/primary-myelofibrosis-pmf/
Accessed at: https://www.mayoclinic.org/diseases-conditions/myelofibrosis/symptoms-
January 6, 2023
NS Pharma opens new U.S drug discovery center in Cambridge, MA
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
Paramus, NJ: January 6, 2023 – NS Pharma announced today the opening of a new office in Cambridge, Massachusetts, to establish the NS Pharma Innovation Research Partnering division.
The new Boston area location is the company’s center for research and development (R&D) in the United States and will diversify Nippon Shinyaku’s R&D portfolio through open innovation. Cambridge, MA, is home to many notable universities, hospitals, research institutions, and bio- venture firms. Establishing a presence in this thriving drug discovery ecosystem enables the company to increase its access to the world’s most advanced seeds of drug discovery technology. The new division will pursue meaningful research collaboration opportunities and promote acceleration and diversification of in-house R&D activities on behalf of Nippon Shinyaku.
“The creation of NS Pharma Innovation Research Partnering division underscores our continued commitment to finding solutions for the unmet needs of patients around the world,” said Tsugio Tanaka, President, NS Pharma, Inc. “As a leader in scientific innovation, Cambridge, MA, will be a natural fit as a hub for our future research collaborations, and we are thrilled to be joining this vibrant community.”
[Office Profile]
Name: NS Pharma, Innovation Research Partnering
Address: One Broadway, Floor 14, Cambridge, Massachusetts, 02142, USA
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit
http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.
Contact
U.S. Media Contact: media@nspharma.com
NEWS RELEASE